Company ProfilePremium

Chong Kun Dang Pharmaceutical Corp.

Company Profile Analysis

Ticker: 185750.KS주식회사 종근당

ESOMAR 23 Corporate BadgeISO Certifications Badge
Chong Kun Dang Pharmaceutical Corp. - Company showcase

Year Founded & Workforce

1941

2,304 Employees

Chong Kun Dang Pharmaceutical Corp. logo

Chong Kun Dang Pharmaceutical Corp. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Chong Kun Dang Pharmaceutical Corp. Overview

Chong Kun Dang is Korea's third-largest traditional pharmaceutical company by 2025 revenue (KRW 1.69 trillion), behind Yuhan and GC Biopharma and ahead of Kwangdong, Daewoong and Hanmi. Its business model combines a large domestic prescription-drug sales force with a portfolio of in-house branded generics and incrementally modified drugs, a handful of domestically discovered new chemical entities, and a heavy and growing book of in-licensed and co-promoted multinational products — currently led by Novo Nordisk's obesity drug Wegovy, Amgen's Prolia and Evenity, MSD's Januvia family and Atozet, and Bayer's Eylia. The company is attempting a strategic pivot from "best-in-Korea commercial partner" to "global innovator", underpinned by the 2023 out-licensing of HDAC6 inhibitor CKD-510 to Novartis (up to USD 1.305 billion), a first-in-house ADC (CKD-703) in US Phase 1/2a, a new NRDO subsidiary (Achella), and a planned KRW 2.2 trillion bio-research complex in Siheung-Baegot. Margins have compressed sharply as low-margin merchandise grows.


What the company does

Chong Kun Dang develops, manufactures, imports and markets human pharmaceuticals, overwhelmingly for the South Korean market. Its revenue is drawn from three sources that management and Korean sell-side analysts track separately:

  1. Own products (제품) — drugs manufactured by the company, including branded generics, fixed-dose combinations and incrementally modified drugs (e.g., Telminuvo), Korean-origin new drugs (e.g., Duvie/lobeglitazone; Camtobell/belotecan), biosimilars (e.g., Nesbell/darbepoetin alfa) and OTC brands (e.g., Penzal).

  2. Merchandise (상품) — finished products bought from licensors or partners and resold, and products co-promoted with multinational and domestic companies (Wegovy, Prolia, Evenity, Januvia/Janumet, Atozet, Prevenar, Eylia, Godex, Dilatrend, Fexuclue, Gliatilin under licence from Italfarmaco).

  3. Licensing and milestone income — technology-transfer revenues, most visibly the USD 80 million upfront payment from Novartis for CKD-510 recognised in FY2023 and a development milestone received in May 2025.

Business and revenue model

The company is fundamentally a product-sales business (prescription and OTC drug sales to hospitals, clinics, wholesalers and pharmacies) supplemented by episodic licensing income. It has no subscription or service revenue of note. Its competitive engine is a nationwide medical-representative network with deep coverage of primary-care clinics in cardiometabolic disease (hypertension, dyslipidaemia, diabetes), which multinational originators rent through co-promotion contracts. This explains the most important structural fact about Chong Kun Dang's P&L: as co-promoted merchandise grows, revenue rises but gross margin falls, because the company books the gross sale while keeping only a distribution/promotion margin.

The dynamic is visible in the numbers. Gross margin was 39.7% in FY2023 (boosted by the Novartis upfront), 33.6% in FY2024 and 31.1% in FY2025, and Korean press reports a cost-of-sales ratio in the low-70% range in Q2 2026 versus the high-60% range a year earlier (Money Today, 5 Aug 2026; Dailian, 31 Jul 2026). A 2026 Korea Ratings analyst comment (via New Daily, 6 Jul 2026) characterised the expected trajectory as sustained top-line growth from new co-promotions (Wegovy, Godex, Fexuclue) but profitability below 2023–2025 levels because of the rising merchandise mix.

Value-chain position

Chong Kun Dang is vertically integrated across formulation development, finished-dosage manufacturing (principally at its Cheonan plant), regulatory affairs and domestic commercialisation. Active pharmaceutical ingredients are largely sourced externally or from sister companies (Chong Kun Dang Bio and Kyongbo Pharm, both controlled by Chong Kun Dang Holdings, not by the listed company). Discovery research is conducted at the Hyojong Research Institute in Yongin, Gyeonggi Province. In licensing deals the company acts as an early-to-mid-stage originator (CKD-510 was out-licensed after Phase 1) rather than a late-stage global developer.

Customers and end-markets

Customers are Korean hospitals (tertiary, general), primary-care clinics, pharmacies and pharmaceutical wholesalers, with reimbursement determined by the National Health Insurance Service (NHIS) and Health Insurance Review & Assessment Service (HIRA). End-markets by therapy: cardiovascular/metabolic (the core franchise), obesity (Wegovy since Oct 2025), bone health (Prolia, Evenity), CNS/cognition (Gliatilin), vaccines (Prevenar), ophthalmology (Eylia, from Dec 2025), hepatology (Godex), gastroenterology (Fexuclue), oncology and transplant/immunology. Exports and overseas sales are small; a geographic split was not found in the sources reviewed.

Company self-description vs independent characterisation

Company framing (paraphrased from the March 2026 AGM address by CEO Kim Young-joo): the company sustained growth through its established and newly introduced products, accepted lower profit in exchange for higher R&D investment, and will pursue "substantive" profit growth in 2026 through timely launches, product competitiveness and market responsiveness, while using the NRDO subsidiary Achella to raise R&D efficiency and building the Baegot bio complex to reach global-level bio capability (Dailypharm and Medifonews, 26 Mar 2026).

Independent characterisation: Chong Kun Dang today is best understood as a high-revenue, low-margin domestic commercial platform with an option on a small number of global R&D assets. Roughly a third of revenue appears to come from the top handful of in-licensed brands; Wegovy alone was the company's largest product in Q1 2026 at about KRW 48.8 billion (New Daily, 6 Jul 2026), around 11% of standalone quarterly sales. Organic own-brand growth is modest and under regulatory pressure (choline alfoscerate re-evaluation; the August 2026 generic price reform). The equity story therefore rests on (a) Novartis's progress with CKD-510 in atrial fibrillation, (b) CKD-703's early clinical data, and (c) management's ability to fund a KRW 2.2 trillion research complex without impairing a balance sheet that has moved from net cash to modest net debt.

Strategy

Stated strategic themes (paraphrased; FY2024–FY2025 AGMs and disclosures)

  1. From sales company to innovator: shift the centre of gravity from co-promoted products to proprietary drugs, focusing on first-in-class and unmet-need medicines.

  2. Platform breadth: build in-house platforms beyond small molecules — ADCs, antibodies, and cell and gene therapy (Mar 2025 AGM).

  3. R&D operating model: a "three-pillar" structure — the parent focuses on discovery and biologics research plus CKD-510/CKD-703; Achella (NRDO) runs clinical development and commercialisation of transferred assets; Neurateon handles formulation and technology research.

  4. Infrastructure: Siheung-Baegot bio complex to give the company end-to-end biologics R&D and process-validation capability.

  5. Near-term earnings defence: timely launches, product competitiveness and diversified co-promotion contracts (ten sales/distribution contracts signed after the K-CAB exit, per Dailypharm Sep 2025).

Initiatives in the last 24 months

InitiativeDateDetail
Baegot site selection and MOUFeb–Jun 2025Preferred bidder; MOU and land contract with Siheung City; KRW 2.2 tn plan
Exchangeable bond for Baegot30 Sep 2025KRW 61.1 bn private EB exchangeable into 626,712 treasury shares at KRW 97,500 (exchange window Nov 2025–Sep 2030); proceeds earmarked for Baegot
Wegovy partnershipSep 2025Entry into obesity
Achella NRDOOct 2025Spin-out of CKD-508, CKD-514, CKD-513
Eylia partnershipDec 2025Entry into retinal disease
Woori Bank frameworkMay 2026KRW 1 tn financial support over five years
Baegot facility investmentJun 2026KRW 392.5 bn through Aug 2028
Neurateon2,026R&D technology subsidiary
CKD339 Phase 3Jul 2026Late-stage domestic cardiovascular asset

Guidance and targets

Chong Kun Dang does not publish formal numeric guidance. Management's qualitative 2026 objective is profit growth after two years of decline. Sell-side expectations imply FY2026 standalone revenue of ~KRW 1.90 tn and flat operating income of ~KRW 79.5 bn, with growth of 3% or less in operating profit according to a Money Today summary of broker views (Aug 2026).

Products & Services

Major in-licensed / co-promoted products (merchandise)

Product (INN)Partner / originatorTherapy areaDescription and statusLatest disclosed sales
Wegovy (semaglutide 2.4 mg)Novo Nordisk KoreaObesityOnce-weekly GLP-1 RA injection; Korean launch Oct 2024; co-promotion with CKD from 1 Oct 2025 to hospitals and clinics. Korea's #1 Rx product by sales in Q2 2025 (IQVIA, per Kukinews)~KRW 48.8 bn in Q1 2026 (company's #1 product); ~KRW 45 bn est. Q2 2026; ~KRW 190 bn est. FY2026
Prolia (denosumab)Amgen KoreaOsteoporosisTwice-yearly RANKL antibody; patent expired Apr 2025, triggering price cuts~KRW 30.0 bn in Q1 2026 (-33.3% YoY)
Evenity (romosozumab)Amgen KoreaOsteoporosisSclerostin antibody; cited as a key Q2 2026 growth driver—
Januvia / Janumet / Janumet XR (sitagliptin ± metformin)MSDType 2 diabetesDPP-4 inhibitor franchise, with CKD since 2016; generics have eroded sales since 2023–24K-CAB plus Januvia were ~15.2% of FY2023 sales; declining
Atozet (ezetimibe/atorvastatin)MSDDyslipidaemiaFixed-dose combination; one of the top three productsKRW 102.7 bn FY2024; KRW 108.8–111.3 bn FY2025E
Vytorin (ezetimibe/simvastatin)MSDDyslipidaemiaMature combination—
Prevenar 13 (pneumococcal conjugate vaccine)PfizerVaccinesLong-running distribution; cited as solid in Q2 2026Not disclosed for 2025–26
Eylia (aflibercept)Bayer KoreaOphthalmology (nAMD etc.)Anti-VEGF; agreement Dec 2025; meaningful contributor from H1 2026—
Godex (biphenyl dimethyl dicarboxylate/carnitine combination)Celltrion PharmLiver diseaseCo-promotion since Jan 2024~4% of Q2 2026 sales (Butler.works)
Dilatrend / Dilatrend SR (carvedilol)Celltrion PharmHypertension / heart failureCo-promotion since Jan 2024KRW 67.0 bn FY2024
Fexuclue (fexuprazan)Daewoong PharmaceuticalGERDP-CAB co-marketing since 2024 (K-CAB replacement); DS projected ~6.3% market share—
Gliatilin (choline alfoscerate)Italfarmaco (licensor)Cognitive impairment / dementiaMarket #2 choline brand; selective reimbursement (higher co-pay) from Oct 2025; clinical re-evaluation results submitted Jun 2026KRW 92.9 bn FY2024; ~KRW 14.8 bn Q1 2026 (-29.3% YoY), partly reserved against refund liability

Sources: Kiwoom (Oct 2025), Yuanta (Jul 2025), DS Investment (26 May 2026), New Daily (6 Jul 2026), Money Today (5 Aug 2026), Bizwatch (31 Jul 2026), Dealsite (31 Jul 2026).

Discontinued: K-CAB (tegoprazan, HK inno.N) — co-promotion ended Dec 2023; about KRW 140 bn of annual sales lost (Eugene, Mar 2024).

Own products (selected; detailed specifications are on the company website)

ProductTypeTherapy areaNotes
Telminuvo (telmisartan/S-amlodipine)Incrementally modified FDCHypertensionKRW 41.7 bn FY2022 (Hanwha); later figures not disclosed
Duvie / Duvimet (lobeglitazone ± metformin)Korean new drug (TZD)Type 2 diabetesLicensed for the US per CEO statement (Nov 2023); partner not named in sources
Camtobell (belotecan) †Korean new drugOncology (topoisomerase I inhibitor)Launched 2000s
Nesbell (darbepoetin alfa) †BiosimilarRenal anaemiaOut-licensed for Japan
Lucentis biosimilar (CKD-701) †BiosimilarOphthalmologyApproved in Korea (2022)
ImmotenBranded productOsteoarthritisCited as a growing own product in 2016
Cyclosporine / tacrolimus brands †Branded genericsTransplantLong-established franchise
PenzalOTCAnalgesicFlagship OTC brand

Pricing: drug prices are set by NHIS/HIRA reimbursement listing; product-level prices are not disclosed by the company. The 1 Aug 2026 drug price reform cuts prices of already-listed generics, affecting own-brand generics (Kiwoom, Jul 2026; Dailypharm headlines).

Pipeline (development products)

CodeMechanism / modalityIndicationStage (Oct 2026)Owner
CKD-510 (Novartis: PKN605)Selective HDAC6 inhibitor, non-hydroxamic acid platformAtrial fibrillation (lead); originally Charcot-Marie-ToothPhase 2 by Novartis (NCT07217067, started Oct 2025); listed in Novartis's CRM Phase 2 pipelineNovartis (ex-Korea)
CKD-703c-Met antibody-drug conjugate (in-house antibody + Synaffix platform, MMAE payload)NSCLC and solid tumoursPhase 1/2a (FDA IND Jul 2025, MFDS IND Feb 2026, first patient Apr 2026; 12 sites Korea/US)Chong Kun Dang
CKD-702EGFR/c-Met bispecific antibodyNSCLCPhase 1 (second part)Chong Kun Dang
CKD-508 / ACL-508CETP inhibitorDyslipidaemiaPhase 1 (UK earlier; US Phase 1 started 2024–25)Achella
CKD-514Oral GLP-1 class small moleculeObesity / metabolicPreclinical/earlyAchella
CKD-513BBB-penetrant HDAC6 inhibitorNeurodegenerative diseasePreclinical (data presented Jun 2026)Achella
CKD-339UndisclosedHypertensionPhase 3 IND approved by MFDS (Jul 2026)Chong Kun Dang
Cell & gene therapy, further ADCsPlatformVariousDiscoveryChong Kun Dang

Financial Narrative

All figures KRW billion, consolidated, FY ending 31 Dec. Source: S&P/StockAnalysis unless noted; EBITDA from Paasa (S&P-based); EPS split-adjusted as reported by Paasa.

Income statement

Revenue CAGR FY2021–FY2025: 5.9% (KRW 1,343.6 bn → 1,692.4 bn).

Commentary. The five-year record has three phases. FY2021–22 was steady growth driven by co-promoted cardiometabolic brands and K-CAB, with heavy R&D (12% of sales) holding operating margin near 7%. FY2023 was an outlier: the Novartis upfront flowed almost entirely to gross and operating profit (operating margin 14.8%, net income KRW 212.5 bn) and R&D expense fell as programmes matured or were capitalised. FY2024–25 show the structural problem: K-CAB's exit and Januvia generics removed high-volume products, Prolia's April 2025 patent expiry cut prices on a top-three brand, and the replacements (Godex, Fexuclue and, from Q4 2025, Wegovy) carry thin margins. Gross margin fell 8.6 percentage points in two years, and operating margin reached a five-year low of 4.8% in FY2025 even as revenue hit a record.

Quarterly run-rate (standalone, 2026)

Sources: preliminary disclosure of 31 Jul 2026 (Dailian, Dealsite, Bizwatch); Q1 derived as H1 minus Q2. DS Investment (26 May 2026) cited Q1 operating income of KRW 14.1 bn, which conflicts with the derived KRW 17.6 bn; the derived figure is consistent with the half-year disclosure. Q2 2026 operating margin was 4.2% versus 5.2% in Q2 2025.

Balance sheet

Goodwill is nil; the intangibles line consists of capitalised development costs, licences and other intangibles. Land rose from KRW 112.3 bn to KRW 214.2 bn in FY2025, reflecting the Baegot site purchase (KRW 94.9 bn).

Commentary. The FY2023 windfall turned a modest net-debt position into net cash of KRW 145 bn. That cushion has since been consumed by three forces: (1) an inventory build of KRW 114 bn in FY2024 and KRW 97 bn in FY2025 (linked to new merchandise, notably Wegovy stocking), (2) the Baegot land purchase, and (3) higher capitalised intangibles. Total debt nearly doubled in FY2025 to KRW 367.8 bn, including KRW 217.7 bn of new long-term borrowings and the exchangeable bond. By Jun-2026, S&P shows total debt of KRW 437.4 bn and net debt of KRW 108.1 bn. With KRW 392.5 bn of facility spending committed through Aug 2028 and a KRW 1 tn five-year credit framework signed with Woori Bank in May 2026, leverage will rise further.

Cash flow

Commentary. Excluding FY2023, operating cash flow has been weak relative to earnings — FY2021–25 cumulative OCF ex-FY2023 was KRW 212 bn against cumulative net income ex-FY2023 of KRW 310 bn — because working capital (inventory and receivables) has absorbed cash as the merchandise book grew. TTM to Jun-2026, OCF recovered to KRW 123.3 bn, but capex of KRW 188.7 bn pushed FCF to -KRW 65.4 bn. Shareholder returns are small (dividends ~KRW 14 bn per year at peak; the FY2025 DPS cut to KRW 500 roughly halves the cash outlay in 2026).

Ratios

S&P's own TTM figures (Oct 2026): ROE 8.2%, ROA 2.9%, ROIC 6.9%, current ratio 2.04, debt/equity 0.43, interest coverage 9.7x, asset turnover 1.06x.

Commentary. Returns have mean-reverted to high single digits after the FY2023 spike. The most concerning trend is the cash conversion cycle lengthening by nearly 40 days since FY2023, entirely through inventory, at the same time as interest-bearing debt is rising.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment and Segment Margins & Growth (%)

MetricFY2023FY2024FY2025

Pharmaceuticals segment revenue (KRW Bn)

1,669.41,586.41,692.4

Segment operating income (KRW Bn)

246.699.580.6

Segment operating margin (%)

14.86.34.8

Segment revenue YoY growth (%)

12.2-5.06.7

Share of total revenue (%)

100100100

Revenue by Segment

MetricFY2023FY2024FY2025

Standalone revenue (KRW Bn)

1,649.61,559.31,681.2

Standalone operating income (KRW Bn)

240.888.180.1

Consolidated revenue (KRW Bn)

1,669.41,586.41,692.4

Consolidated operating income (KRW Bn)

246.699.580.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Group Entities

EntityRelationshipRole

Chong Kun Dang Holdings Corp. (KRX: 001630)

Parent; ~39.3% with related parties

Pure holding company; chairman Lee Jang-han; CEO Choi Hee-nam

Chong Kun Dang Pharmaceutical Corp. (185750)

Listed operating company

—

Achella (아첼라)

Subsidiary, est. Oct 2025

NRDO: clinical development and commercialisation of CKD-508 (now ACL-508), CKD-514, CKD-513

Neurateon (뉴라테온)

Subsidiary, launched 2026

R&D specialist: formulation and technology research

US research entity

Subsidiary

—

PT CKD OTTO Pharmaceuticals †

Indonesian joint venture

—

Chong Kun Dang Bio (063160), Kyongbo Pharm (214390), Chong Kun Dang Health, Chong Kun Dang Industry

Sister companies under Holdings

APIs, fermentation, health functional foods; not consolidated by 185750

Income Statement and Margin Analysis (%)

MetricFY2021FY2022FY2023FY2024FY2025

Revenue (KRW Bn)

1,343.61,488.31,669.41,586.41,692.4

Revenue growth YoY (%)

3.110.812.2-5.06.7

Cost of revenue (KRW Bn)

847.7945.71,007.21,053.81,166.0

Gross profit (KRW Bn)

495.8542.6662.2532.6526.4

SG&A (KRW Bn)

221.0237.9256.6267.8270.6

R&D expense, expensed (KRW Bn)

163.3176.3140.2143.9154.1

Operating income (KRW Bn)

94.8109.9246.699.580.6

EBITDA (KRW Bn)

112.7137.6287.6150.1125.4

Net income (KRW Bn)

42.781.0212.5109.177.5

EPS basic (KRW)

3,1186,60916,7048,2075,882

Gross margin (%)

36.936.539.733.631.1

Operating margin (%)

7.17.414.86.34.8

EBITDA margin (%)

8.49.217.29.57.4

Net margin (%)

3.25.412.76.94.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (Quarterly)

MetricQ1 2026Q2 2026H1 2026

Standalone revenue (KRW Bn)

447.7475.4923.1

Revenue YoY (%)

12.210.711.4

Standalone operating income (KRW Bn)

17.619.937.5

Operating income YoY (%)

36.4-10.17.1

Standalone net income (KRW Bn)

14.918.032.9

Balance Sheet and Per-Share Data

MetricFY2021FY2022FY2023FY2024FY2025

Total assets (KRW Bn)

1,046.71,124.91,402.41,458.81,800.3

Cash & equivalents (KRW Bn)

131.8117.4219.6228.5216.2

Cash + short-term investments (KRW Bn)

187.3155.9365.1302.2346.5

Accounts receivable (KRW Bn)

203.6248.4269.6266.7265.8

Inventory (KRW Bn)

224.7270.1261.4353.8428.6

PP&E (KRW Bn)

298.9310.7319.8320.8437.7

Goodwill & intangibles (KRW Bn)

20.827.052.174.590.0

Short-term debt incl. current portion & leases (KRW Bn)

102.1124.4184.869.5165.9

Long-term debt incl. leases (KRW Bn)

135.0111.335.0118.7201.9

Total debt (KRW Bn)

237.1235.7219.8188.2367.8

Net debt (KRW Bn)

49.779.9-145.3-114.021.3

Total liabilities (KRW Bn)

480.9503.6586.8562.4793.9

Shareholders' equity (KRW Bn)

565.8621.3815.6896.41,006.4

Working capital (KRW Bn)

346.9339.4435.1593.6575.7

Book value per share (KRW)

41,43346,31561,04967,74876,180

Cash Flow

MetricFY2021FY2022FY2023FY2024FY2025

Operating cash flow (KRW Bn)

12.967.7318.264.367.4

Capital expenditure (KRW Bn)

48.244.941.238.5140.9

Free cash flow (KRW Bn)

-35.322.8276.925.8-73.6

Purchase of intangibles (KRW Bn)

3.68.227.627.538.2

Change in inventory (KRW Bn)

-53.8-54.5-6.0-114.3-96.6

Dividends paid (KRW Bn)

10.811.211.613.313.8

Share buybacks (KRW Bn)

1.91.96.016.01.8

Net debt issued / (repaid) (KRW Bn)

97.9-3.2-26.1-33.7182.5

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE (%)

7.513.629.612.78.1

ROA (%)

4.17.516.87.64.8

ROIC, after 24% notional tax (%)

11.711.928.09.76.0

Current ratio (x)

2.081.911.852.612.12

Debt / equity (x)

0.420.380.270.210.37

Net debt / EBITDA (x)

0.440.58-0.51-0.760.17

Interest coverage, EBIT / cash interest (x)

25.217.128.613.012.9

Asset turnover (x)

1.281.371.321.111.04

Days sales outstanding (days)

5561596157

Days inventory outstanding (days)

9710495123134

Days payables outstanding (days)

5656676967

Cash conversion cycle (days)

9610987115125

Capital Markets

ItemValueSource / date

Share price

KRW 65,200

14 Oct 2026

52-week change

-19.2%

S&P

YTD change

-20.5%

Paasa (mid-2026)

5-year change

-32.7%

Paasa (mid-2026)

52-week high (2025)

KRW ~121,100 (adjusted)

Yuanta, Jul 2025

200-day / 50-day MA

KRW 78,049 / 67,034

S&P

Beta (5Y)

0.24

S&P

Trailing P/E

11.0x

S&P

Forward P/E

12.8x

S&P

EV/EBITDA

8.0x

S&P

EV/Sales

0.55x

S&P

P/B

0.85x

S&P

Per-Share Data and Margin Analysis (%)

MetricFY2024FY2025

Cash DPS (KRW)

1,100500

Dividend yield at payment (%)

1.20.8

Stock dividend (%)

50

Analyst Conclusions

Guidance and consensus

No formal guidance. Broker forecasts (Naver-hosted note, 21 Jul 2026) project standalone revenue of KRW 1.903 tn in FY2026 and KRW 1.982 tn in FY2027, with operating income of KRW 79.5 bn and KRW 89.7 bn respectively; Wegovy is forecast at about KRW 190 bn in FY2026. S&P consensus shows 3-year revenue growth of 5.5% and EPS growth of -2.9%.

Bull case

  1. CKD-510 success: positive Phase 2 data in AF would trigger milestones and justify the KRW 210–240 bn rNPV estimates — roughly a quarter of the current market cap.

  2. Mean-reverting valuation: at 0.85x book and 8x EV/EBITDA, the stock prices in little for the pipeline or for margin recovery.

  3. Scale effect: a KRW 1.9 tn revenue base with stable SG&A could deliver operating leverage once R&D spending plateaus.

Bear case

  1. Structural margin decline: merchandise growth keeps operating margin near 4–5%, below Hanmi and Daewoong.

  2. Choline clawback: indication deletion would remove a top product and trigger a cash refund.

  3. Capex and leverage: KRW 2.2 tn Baegot plan versus FCF that has been negative in FY2025 and TTM.

Catalysts and monitorables (next 12 months)

  • Q3 2026 results (26 Oct 2026) and FY2026 results (Feb 2027).

  • MFDS decision on choline alfoscerate indications and refund quantum.

  • Novartis disclosures on CKD-510 Phase 2.

  • CKD-703 dose-escalation data and any partnering.

  • CKD339 Phase 3 progress.

  • Wegovy share trends versus Mounjaro.

  • Baegot construction and financing.

  • CEO term expiry at the March 2027 AGM.

  • Dividend policy for FY2026.

Analyst verdict

Chong Kun Dang is a company at an awkward midpoint between two business models. As a domestic commercial platform it is arguably best in class: it replaced the loss of K-CAB, Korea's leading gastrointestinal brand, within two years and grew revenue to a record KRW 1.69 tn, and it has become the default partner for multinationals entering primary care — most recently Novo Nordisk with Wegovy and Bayer with Eylia. But that success comes at the cost of profitability. Each new co-promotion adds revenue at a thin margin, pushing gross margin down by nearly nine points in two years and operating margin to below 5%, while working capital has absorbed cash and the balance sheet has moved back into net debt.

The innovator thesis is real but narrow. CKD-510 is the only asset with external validation; its fate rests with Novartis, and its value will be determined by Phase 2 data in atrial fibrillation. CKD-703 has only just dosed its first patient. The rest of the pipeline is early, and the Achella and Neurateon structures, while sensible, have yet to prove they can attract outside capital.

Meanwhile, management has committed to the most ambitious capital programme in the company's history at the moment when cash generation is weakest and the choline alfoscerate verdict is pending. The dividend cut signals that management recognises the funding tension.

Our assessment is that the shares, at 0.85x book and roughly 11x trailing earnings, already discount much of the margin pressure, and that CKD-510 offers asymmetric upside. However, near-term earnings visibility is poor, and investors should expect the regulatory overhang (choline, price reform) and Baegot funding to dominate the next two to four quarters. We characterise the stock as a pipeline-optionality hold with a negative earnings bias, where the key swing factors are the choline decision and CKD-510 Phase 2 readout timing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundAge

Kim Young-joo

President & CEO, inside director

CEO since Mar 2015; reappointed Mar 2024 (term to the 2027 AGM). Microbiology degree, Korea University; MS in immunology, Long Island University; previously at Merck, credited with building its prescription business and, at CKD, with tripling revenue and securing the Novartis licence

Born 1964 (≈62)

Lee Kyu-woong

Head of Marketing Division, inside director

Reappointed Mar 2026

—

Kwon Yoo-kyung

Head of Development Center, inside director

Newly appointed Mar 2026

—

Lee Dong-ha

Head of Planning Team, inside director

Appointed Mar 2024

≈52

Lee Mi-yeop

Head of Product Development Division

Spokesperson for CKD-510 licence (2023)

—

Lee Chang-sik

Research Director

Leads ADC programme (CKD-703)

—

Lee Woo-ram

Standing statutory auditor

Appointed Mar 2026; former audit partner (상무), Samil PwC

—

“—” = not publicly disclosed.

Executive Leadership Team — Lee Jang-han

NameRole

Lee Jang-han

Chairman, Chong Kun Dang Holdings; controlling family

Choi Hee-nam

CEO, Chong Kun Dang Holdings (since Mar 2024); former IMF executive director and Korea Investment Corporation CEO

Lee Hee-jae

Inside director, Holdings (ex-CJ Corp. M&A head), appointed 2024

Park Wan-gap

CEO, Chong Kun Dang Bio (2024)

Major Shareholders

HolderStakeSource

Chong Kun Dang Holdings + 5 related parties

~39.3%

Kiwoom, Oct 2025

Foreign investors (aggregate)

~14.2%

Kiwoom, Oct 2025

Minority shareholders (40,640 holders)

32.13%

DART FY2025

Treasury shares

~4.5% of issued (626,712 shares earmarked for the 2025 exchangeable bond)

Dealsite, Sep 2025; S&P share count

Institutions (aggregate, S&P)

28.3%

S&P, Oct 2026

Competitive Landscape

Peer Comparison FY2025

CompanyFY2025 revenue (KRW Bn)FY2025 OP (KRW Bn)OP margin (%)Positioning vs CKD

Yuhan Corp.

2,186.6104.44.8

#1 traditional pharma; Leclaza (lazertinib) global royalties; similar in-licensed model

GC Biopharma

1,991.369.13.5

Plasma and vaccines; Alyglo US sales USD 106 m in 2025

Chong Kun Dang

1,692.480.64.8—

Kwangdong Pharmaceutical

1,659.531.01.9

Consumer health / beverages

Daewoong Pharmaceutical

1,570.9196.812.5

Fexuclue, Envlo, Nabota exports; CKD partner and competitor

Hanmi Pharmaceutical

1,547.5257.816.7

Own-brand combinations (Rosuzet, Amosartan); highest profitability

HK inno.N

1,063.2110.910.4

K-CAB owner (former CKD partner)

Boryung

1,017.465.16.4

Kanarb family; Bizwatch cites revenue of KRW 1,036.0 bn (discrepancy)

Daewoong Bio

———

Gliatamin, #1 in choline alfoscerate (direct Gliatilin competitor)

Celltrion Pharm, Dong-A ST, Jeil, Ildong

———

Cardiometabolic primary-care competitors

Eli Lilly Korea and its Mounjaro partner

———

Direct competitor to Wegovy in obesity

Peer Comparison FY2025 — Revenue

MetricChong Kun DangYuhanHanmiDaewoong

Revenue (KRW Bn)

1,692.42,186.61,547.51,570.9

OP margin (%)

4.84.816.712.5

Revenue growth (%)

6.7———

R&D intensity (%)

~11

———

Company Snapshot

$1,191M

Revenue

2,304

Employees

1941

Founded

Seoul, South Korea

Headquarters

SWOT Analysis

Strengths

  • Scale: third-largest traditional pharma in Korea with KRW 1.69 tn FY2025 revenue (Bizwatch, Feb 2026).
  • Partner of choice: signed ten sales/distribution contracts after the K-CAB exit, including Wegovy and Eylia (Dailypharm, Sep 2025).
  • R&D validation: CKD-510 licence of up to USD 1.305 bn; Novartis has advanced it into Phase 2 and lists it among core CRM assets (Mirae Asset, Feb 2026).
  • Sustained R&D commitment: expensed plus capitalised R&D of 10–12% of sales every year FY2021–25 (S&P).
  • Balance-sheet capacity: equity of KRW 1.01 tn and debt/equity of 0.37x at FY2025 (S&P).
  • Management continuity: the same CEO since 2015, during which revenue roughly tripled (Dailypharm, Feb 2024).

Weaknesses

  • Margin erosion: gross margin down from 39.7% (FY2023) to 31.1% (FY2025); Q2 2026 OP margin only 4.2%.
  • Merchandise dependence: cost-of-sales ratio in the low-70s in Q2 2026 (Money Today).
  • Cash conversion: CCC lengthened from 87 days (FY2023) to 125 days (FY2025); FCF was -KRW 73.6 bn in FY2025.
  • Partner concentration: Wegovy ≈ 9–11% of quarterly sales; K-CAB precedent shows termination risk.
  • Domestic concentration: no meaningful geographic diversification disclosed.
  • Weak shareholder returns: DPS cut from KRW 1,100 (FY2024) to KRW 500 (FY2025); yield ~0.8%.

Opportunities

  • CKD-510 milestones/royalties: USD 1.225 bn of remaining milestones; Yuanta rNPV KRW 238.6 bn (Apr 2026).
  • CKD-703 data: Phase 1/2a across 12 sites could support a licensing deal.
  • Obesity market expansion: Wegovy plus internal CKD-514 (oral GLP-1).
  • Achella NRDO: potential external funding or partnering of ACL-508, CKD-514, CKD-513.
  • CKD339 Phase 3: potential new proprietary cardiovascular product.
  • Baegot complex: biologics capability and potential cluster partnerships with Seoul National University's Siheung campus.

Threats

  • Choline alfoscerate: primary endpoint missed in the MCI study; if indications are deleted, a 20% clawback of reimbursed sales since trial approval applies (Bizwatch, Sep 2026).
  • Price reform: generic price cuts from 1 Aug 2026 (Kiwoom).
  • Wegovy competition: Mounjaro and future oral and generic semaglutide.
  • Prolia erosion: -33% YoY in Q1 2026.
  • Funding strain: KRW 1.71 tn of the Baegot plan still to fund (CEO Score Daily).
  • Licensor decisions: Novartis controls CKD-510's fate; hand-back would remove the pipeline valuation.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Prolia patent expiry; price cutErodes a top-three product (Q1 2026 sales -33% YoY)
May 2025Milestone from Novartis on CKD-510 Phase 2 INDEnds concerns about a possible hand-back after a quiet year
Jun 2025Siheung City MOU and land contract (KRW 2.2 tn plan)Launch of the largest investment programme
Jul 2025Q2 2025 standalone revenue KRW 429.6 bn, operating income KRW 22.1 bnMerchandise mix pressures margin
25 Jul 2025FDA clears CKD-703 Phase 1/2aFirst in-house ADC enters clinic
18 Sep 2025Wegovy co-promotion signedBecomes largest product by Q1 2026
30 Sep 2025KRW 61.1 bn exchangeable bond approvedFunding Baegot via treasury shares
Oct 2025Achella establishedR&D restructuring
Oct 2025Baegot land purchase (KRW 94.9 bn) executedCapex step-up
Oct 2025Novartis starts CKD-510 Phase 2 in AF (NCT07217067)Indication clarified
Oct 2025Gliatilin moved to selective reimbursement for non-dementia usesVolume decline begins
21 Oct 2025Kiwoom upgrades to Buy, TP KRW 100,000Sell-side support
Dec 2025Eylia agreement with Bayer KoreaNew ophthalmology revenue
26 Feb 2026FY2025 results; Mirae Asset adds CKD-510 value (KRW 210.7 bn)Pipeline begins to be valued
Feb 2026MFDS approves CKD-703 trial in KoreaGlobal trial footprint
26 Mar 202613th AGM: FY2025 revenue KRW 1.6924 tn, OP KRW 80.6 bn; DPS cut to KRW 500; board changesShareholder-return reduction
8 Apr 2026Yuanta values CKD-510 at KRW 238.6 bn rNPV; TP raised to KRW 130,000Bull-case anchor
20 Apr 2026First patient dosed in CKD-703 trial (Ohio)Clinical execution
May 2026Q1 2026 standalone revenue KRW 447.8 bn (+12.2%); Wegovy KRW 48.8 bnGrowth driven by merchandise
May 2026Woori Bank KRW 1 tn financing frameworkFunding capacity
23 May 2026Choline MCI re-evaluation trial misses primary endpoint (company cites positive per-protocol analysis)Raises refund risk
11 Jun 2026KRW 392.5 bn Baegot facility investment approvedCapex commitment equal to 39% of equity
Jun 2026CKD-513 non-clinical data presented internationallyNeurology pipeline
End-Jun 2026Gliatilin re-evaluation results filed with MFDSDecision pending
2026Neurateon launchedR&D restructuring
21 Jul 2026Broker note: FY2026E standalone OP KRW 79.5 bnFlat earnings expected
27 Jul 2026MFDS approves Phase 3 IND for CKD339 (hypertension)Late-stage domestic asset
31 Jul 2026Q2 2026: revenue KRW 475.4 bn (+10.7%), OP KRW 19.9 bn (-10.1%)Margin compression continues
1 Aug 2026Generic drug price reform takes effectPricing headwind for own generics
14 Aug 2026Half-year report filed—
11 Sep 2026Choline re-evaluation conclusion reported as imminent; refund liabilities reclassified to currentPotential cash outflow
Sep 2026Gyeonggi FEZ conditional approval for Baegot building planConstruction path cleared
26 Oct 2026 (expected)Q3 2026 resultsNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

2 charts
Revenue by Segment: Pharmaceuticals segment revenue rose from KRW 1,669.4 Bn in FY2023 to KRW 1,692.4 Bn in FY2025.
Chong Kun Dang Pharmaceutical Corp. — Revenue by Segment
Series (KRW Bn)FY2023FY2024FY2025
Pharmaceuticals segment revenue1,669.41,586.41,692.4
Segment operating income246.699.580.6
Standalone revenue1,649.61,559.31,681.2
Standalone operating income240.888.180.1
Consolidated revenue1,669.41,586.41,692.4
Consolidated operating income246.699.580.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.